|
Post by prcgorman2 on May 22, 2024 14:55:37 GMT -5
I wrote a bunch of stuff last night that I then discarded when I finally posted because it was simply more head scratching over apparent drug price, percentage of patient population being treated, and resulting revenue. That said, castlerockchris makes a good point about the value of curing NTM, not just temporarily ameliorating it. And, his points that MannKind did their homework, shared it with the FDA, got things moving as fast as possible (and I will add going so far as manufacturing their own clofazimine rather than finding another supplier after the supplier had a fire). So while we can't figure out WTF with regard to product pricing, patient population being treated, and total revenues, "things will be good, better than they are now" might be a sufficient conclusion.
P.S. I think it's funny we've spent so much time talking about a drug in the MannKind pipeline which isn't very likely to ever be on TechnoSphere in a thread called "Mannkind | The Rise of Technosphere".
|
|
|
Post by ktim on May 22, 2024 15:20:39 GMT -5
Maybe that plateauing that is depicted is a reflection of the possibility that effective treatment can be a cure and will thus start shrinking what is currently a growing patient population. If MNKD treatment does turn out to be an effective "cure" then it should quickly reach a point where yearly sales reflect the rate of new infections rather than the current large chronic population. Though I really know little about this disease condition. All I know about it is from reading posts here.
|
|
|
Post by agedhippie on May 22, 2024 15:57:39 GMT -5
... Just because I am shocked does not mean hospital insurance companies won’t pay. I do not know what is possible or customary. (Note: agedhippie is who suggested coverage may be via hospital insurance. I didn’t even know there was such a thing.) ... In Medicare terms it's the difference between Part B and Part D.
|
|
rebby
Researcher
Posts: 79
|
Post by rebby on May 22, 2024 16:13:59 GMT -5
If it turns out to be a cure, I’d expect significantly higher rates for market penetration.
|
|
|
Post by prcgorman2 on May 22, 2024 18:24:53 GMT -5
... Just because I am shocked does not mean hospital insurance companies won’t pay. I do not know what is possible or customary. (Note: agedhippie is who suggested coverage may be via hospital insurance. I didn’t even know there was such a thing.) ... In Medicare terms it's the difference between Part B and Part D. Thank you agedhippie. Your reference to Medicare helps, but maybe you meant Part A (hospitalization, hospice, home healthcare, etc.), and or versus Part D as you say for prescription drug coverage.
Any comment on whether the $100,000 per patient is reasonable or customary for treating ailments for orphan diseases like NTM?
|
|